Grief, depression, and anxiety in bereaved caregivers of people with motor neurone disease: a population-based national study.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Samar M AounNatasha Bear

Abstract

Despite the traumatic and fatal nature of motor neurone disease (MND) and the caring experiences being described as unrelenting, little is known about risk of psychiatric morbidity and Prolonged Grief Disorder (PGD) for family caregivers. Methods: A cross-sectional survey of caregivers bereaved in 2016-2018 was distributed by the five MND Associations in Australia (2019). Validated tools for PGD (PG-13), anxiety, depression, and family functioning were included. Multinomial logistic regression was used to compare the factors associated with grief. Findings: Overall, 393 valid responses were received, a 31% response rate. The prevalence of ICD-11 PGD was 9.7%; moderate/severe anxiety 12.3%, moderate/severe depression 18.5% and 18.7% indicated poor family functioning. MND caregivers have higher bereavement risk prevalence than the general bereaved population, with 9.6% in the high-risk group (vs 6.4%) and 54% at moderate risk (vs 35%). Being in the PGD group was 8 or 18 times more likely when the respondent had anxiety or depression, respectively. Poor family functioning significantly increased the likelihood of PGD by four times. Other significant predictors of PGD were a recent bereavement (<12 months), being a spouse/partner o...Continue Reading

References

Sep 15, 2001·Journal of General Internal Medicine·K KroenkeJ B Williams
Jun 2, 2005·JAMA : the Journal of the American Medical Association·Katherine ShearCharles F Reynolds
May 24, 2006·Archives of Internal Medicine·Robert L SpitzerBernd Löwe
Sep 12, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Carole MockfordRaymond Fitzpatrick
Feb 22, 2007·JAMA : the Journal of the American Medical Association·Paul K MaciejewskiHolly G Prigerson
Dec 11, 2007·Lancet·Margaret StroebeWolfgang Stroebe
Aug 5, 2009·PLoS Medicine·Holly G PrigersonPaul K Maciejewski
Dec 15, 2010·Psychology, Health & Medicine·Francesco PagniniEnrico Molinari
Jan 11, 2011·Journal of Affective Disorders·Anette KerstingBirgit Wagner
Feb 8, 2011·Lancet·Matthew C KiernanMargaret C Zoing
Jun 30, 2011·Palliative Medicine·Bridget WhiteheadDouglas Mitchell
Jan 15, 2013·BMC Medical Research Methodology·Katherine J HuntJulia Addington-Hall
May 26, 2015·Journal of Pain and Symptom Management·Emma J BurnsDavid C Currow
Nov 27, 2015·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Samar M AounCarol Birks
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W KissaneFrancesca Del Gaudio
Jan 4, 2017·Journal of Pain and Symptom Management·Mette Kjaergaard NielsenMai-Britt Guldin
Feb 9, 2017·Journal of Affective Disorders·Marie LundorffMaja O'Connor
Oct 19, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Juyeon Oh, Jung A Kim
Jun 12, 2018·European Journal of Psychotraumatology·Clare Killikelly, Andreas Maercker
Jul 31, 2018·Journal of Affective Disorders·Paul A BoelenGeert E Smid

❮ Previous
Next ❯

Citations

Mar 25, 2021·Journal of Pain and Symptom Management·Jacqueline GillespieChristine L Watt
Sep 11, 2020·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Samar M AounDavid W Kissane

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.